# US 11,896,559 B2 · Opthalmic compositions comprising F6H8

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,559 B2
- Document ID: US11896559B2
- Status: Granted
- Kind: B2
- Application number: 16/753,701
- Filed: 2018-10-03
- Published: 2020-08-27
- Granted: 2024-02-13
- Earliest claimed: 2017-10-04
- Assignees: Novaliq GmbH
- Applicants: Novaliq GmbH
- Inventors: Bernhard Günther; Frank Löscher; Hartmut Voss; Sonja Krösser; Kirsten Eickhoff; Daniela Willen; Markus Beier; Thomas Schlüter
- Web page: https://patentgrep.com/patent/US11896559B2

## CPC

- A61K 31/02: Halogenated hydrocarbons
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

## Claims

### Claim 1

A method of increasing tear film thickness and/or increasing the lipid layer thickness, wherein the method comprises the steps of: (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF2)6(CH2)8H and 2-perfluorohexyloctane, optionally wherein the amount is effective to enrich an ophthalmic tissue in F(CF2)6(CH2)8H, and optionally (b) delayed release of F(CF2)6(CH2)8H from the enriched ophthalmic tissue;
wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid eye drops; and
wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method is effective to enrich an ophthalmic tissue in F(CF2)6(CH2)8H.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ophthalmic tissue enriched in F(CF2)6(CH2)8H is the palpebral conjunctiva, the cornea, the Meibomian glands, the lacrimal glands and/or the bulbar conjunctiva.

### Claim 4 (depends on 3)

The method of claim 3, wherein the Meibomian glands comprise 0.0001 to 0.05 wt % of F(CF2)6(CH2)8H.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition consists of F(CF2)6(CH2)8H and up to 3 wt. % of 2-perfluorohexyloctane, based on the total weight of the composition.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition consists of F(CF2)6(CH2)8H and up to 1 wt.% of 2-perfluorohexyloctane, based on the total weight of the composition.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the patient suffers from Meibomian gland dysfunction, and/or the keratoconjunctivitis sicca (dry eye disease) is due to Meibomian gland dysfunction.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the patient is non-responsive to traditional physical methods of treating Meibomian Gland Dysfunction and/or is non-responsive to treatment with aqueous ophthalmic eye drop compositions.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition is administered in a dose of a single drop per eye less than four times per day.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the composition is administered in a dose of a single drop of 10-12 μl per eye two times per day.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient is characterized by at least 2 of the criteria selected from the group consisting of:
(i) a total ocular surface disease index (OSDI) of higher than 25;
(ii) a total corneal fluorescein staining (NEI scale) between 4 and 11;
(iii) a Schirmer's Test I greater than 5 mm; and
(iv) an MGD score of higher than 3.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method is effective in treating (reducing) simultaneously the ocular surface damage of one or more corneal regions, and the symptoms of dryness of the patient, wherein the patient suffers from Meibomian gland dysfunction, and/or the keratoconjunctivitis sicca (dry eye disease) is due to Meibomian gland dysfunction.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the ocular surface damage of one or more corneal regions is selected from the group consisting of:
(i) ocular surface damage of the total corneal region;
(ii) ocular surface damage of the central corneal region;
(iii) ocular surface damage of the nasal corneal region;
(iv) ocular surface damage of the temporal corneal region; and
(v) combinations thereof.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the one or more symptoms of dryness are selected from the group consisting of:
(i) severity of dryness;
(ii) blurred vision;
(iii) sensitivity of light;
(iv) frequency of dryness;
(v) awareness of dryness; and
(vi) any combination thereof.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the ophthalmic composition is administered in a dose of a single drop of 10-11 μl per eye two to four times per day.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the method is a method of increasing the lipid layer thickness, and wherein the method is effective to increase lipid layer thickness immediately after drop instillation and/or continuously over a treatment period of 4 weeks.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the patients are suffering from mild to moderate keratoconjunctivitis sicca (dry eye disease).

### Claim 18 (depends on 1)

The method according to claim 1, wherein the tear film thickness is increased after a single dose of the composition.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the tear film thickness is increased within ten minutes of administration of a dose of the composition.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the composition is administered for at least two weeks and the lipid layer thickness is improved after 2 weeks of treatment.